Novartis snaps up PI3Kα breast cancer drug in $3bn deal
Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a hefty $2 billion upfront for the asset, which is in phase 1/2 testing. The deal, which includes another $1 billion potential …